KaloBios Initiates Phase 2 Expansion Portion of Study of KB004 in Hematologic Malignancies

KaloBios Pharmaceuticals (Nasdaq: KBIO ) today announced that the company has begun treating patients in the Phase 2 expansion portion of study KB004-01 evaluating KB004, the company's anti-EphA3 Humaneered® monoclonal antibody (mAb). The company is targeting enrollment of 30 patients for this portion of the Phase 2 expansion focusing